DIMERx Gains Global Rights to New Amino Acid Prodrug from Massachusetts General Hospital

DIMERx, Inc., a biopharmaceutical firm at an advanced stage of development, has recently procured exclusive rights from Massachusetts General Hospital (MGH) for a pioneering amino acid dimer. This dimer is set to be developed for two rare disease indications within the United States and as a unique medical food for markets outside the U.S. This exclusive patent licensing agreement is a significant milestone in leveraging amino acids' therapeutic potential as drugs. Through this strategic partnership, DIMERx is poised to revolutionize treatment approaches across various health conditions.

The innovative dimer was developed and patented by Dr. Maurizio Fava, Chair of Psychiatry at MGH, along with Dr. Xudong Huang, Co-Director of the Neurochemistry Lab at the MGH Department of Psychiatry. The molecule exhibits substantial therapeutic promise, and DIMERx is enthusiastic about delivering this groundbreaking treatment to patients. Dr. Fava expressed his excitement about the collaboration, stating, “I am delighted that DIMERx and MGH have entered into this agreement. DIMERx has been at the forefront of harnessing the therapeutic potential of compounds with covalent bonds through dimerization. The company has a robust scientific foundation within the small molecule modality and boasts visionary leadership. DIMERx is the right partner, and we are looking forward to advancing the dimer from paper to patients.”

DIMERx’s co-founders, Nikhilesh Singh, M.Pharm., Ph.D., Chief Executive Officer, and Gregory Beyer, Chief Financial Officer, shared their enthusiasm about the compound's transformative potential. Dr. Singh remarked, “This significant milestone marks a pivotal moment for DIMERx, and we are incredibly grateful to Dr. Fava for the opportunity to collaborate with him and one of the leading research institutes in the world.”

DIMERx, Inc. is a clinical-stage biopharmaceutical company dedicated to developing a novel platform of first-in-class dimer therapeutics. The company’s flagship product, DMX-101, has shown promising results in terms of safety, tolerability, and effectiveness in controlling abdominal pain and gastrointestinal motility during a Phase 2 study. DIMERx is currently exploring financing options that align with its vision of establishing itself as a transformative drug company specializing in small molecule dimers.

The collaboration between DIMERx and MGH opens doors to numerous opportunities for future partnerships and advancements in the field of biopharmaceuticals. The shared vision and expertise of both entities are expected to drive significant progress in developing treatments for rare diseases and proprietary medical food applications. This strategic alliance underscores the potential of amino acid dimers in providing innovative therapeutic solutions and highlights the importance of collaborative efforts in advancing medical research and development.